Deutsche Bank Aktiengesellschaft Lowers Eli Lilly and Company (NYSE:LLY) Price Target to $900.00

Eli Lilly and Company (NYSE:LLY) had its price target decreased by equities research analysts at Deutsche Bank Aktiengesellschaft from $1,010.00 to $900.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential upside of 40.73% from the company’s current price.

Several other equities research analysts have also recently issued reports on the stock. Leerink Partners reaffirmed a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target on the stock. Finally, Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $977.65.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $639.50 on Monday. The company has a 50-day simple moving average of $769.64 and a 200-day simple moving average of $797.19. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market capitalization of $605.26 billion, a PE ratio of 41.80, a P/E/G ratio of 0.89 and a beta of 0.44. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the firm posted $3.92 EPS. The firm’s revenue for the quarter was up 37.6% on a year-over-year basis. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This represents a 2.14% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds have recently added to or reduced their stakes in the company. Country Trust Bank boosted its position in Eli Lilly and Company by 0.9% in the second quarter. Country Trust Bank now owns 95,690 shares of the company’s stock worth $74,593,000 after purchasing an additional 894 shares during the last quarter. Richmond Investment Services LLC increased its stake in Eli Lilly and Company by 123.0% in the 2nd quarter. Richmond Investment Services LLC now owns 1,224 shares of the company’s stock worth $954,000 after acquiring an additional 675 shares during the last quarter. J.W. Cole Advisors Inc. increased its stake in Eli Lilly and Company by 33.5% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 25,109 shares of the company’s stock worth $19,573,000 after acquiring an additional 6,301 shares during the last quarter. FourThought Financial Partners LLC increased its stake in Eli Lilly and Company by 36.1% in the 2nd quarter. FourThought Financial Partners LLC now owns 3,160 shares of the company’s stock worth $2,463,000 after acquiring an additional 839 shares during the last quarter. Finally, Associated Banc Corp increased its stake in Eli Lilly and Company by 1.6% in the 2nd quarter. Associated Banc Corp now owns 55,366 shares of the company’s stock worth $43,159,000 after acquiring an additional 869 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.